3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Carcinoma, Transitional Cell
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Melanoma
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Glioblastoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
6
Nivolumab
3
Gemcitabine
3
Cisplatin
3
Carboplatin
3
brigimadlin
2
Ramucirumab
2
Fluorouracil
2
Docetaxel
2
Cetuximab
2
tucatinib
1
trifluridine tipiracil drug combination
1
tremelimumab
1
trametinib
1
regorafenib
1
pertuzumab
1
milademetan
1
larotrectinib
1
futibatinib
1
durvalumab
1
cemiplimab
1
adagrasib
1
Trastuzumab
1
TAS-116
1
Ritonavir
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Omacor
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
regorafenib
×
Thoracic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled